Back to the main directory
Company Analysis / Equity
- INUV: Zacks Company Report A Potentially Tepid Q2 Could Prove a Buying Opportunity by Zacks
- TEUM: Kitchen Sink Quarter Restructures the Company for Growth by Zacks
- ETAK: Restructuring Progress, But More to Come by Zacks
- ABDC: Zacks Company Report Q2 - The Gain on Sale of ACT Lighting Impacts Q2 Positively by Zacks
- ETAK: Zacks Company Report Initiating Coverage-Company Rightsizes After Customer Loss by Zacks
- 2015 Earnings Review and 2016 Milestones for RI-002 by Zacks
- 3Q:16 Results. Incremental Progress on CMC Issue Resolution. by Zacks
- ABDC: Q4 Takes a Hit on an Investment Sale by Zacks
- ADMA: Files BLA for RI-002 with FDA Approval on Track for Second Half of 2016 by Zacks
- ADMA: Moving Forward with RI-002; On Track for Second Half 2016 Approval by Zacks
- ADXS: Phase III of AXAL for cervical cancer initiated, Multiple progresses have been made to advance its clinical programs by Zacks
- AEMD: Upgrading to Buy on Operational, Financial Progress by Zacks
- ADXS: Balance boosted by recent financing, Phase III of ADXS-HPV for cervical cancer will be initiated by the end of year---Buy by Zacks
- ADXS: Clinical hold lifted, Phase III of ADXSHPV for cervical cancer will be initiated by the end of year---Buy by Zacks
- ADXS: EOP2 meeting with the FDA on the way, Pivotal Phase III planned, Balance sheet boosted; on track to advance its pipeline -- Outperform by Zacks
- ADXS: Multiple progresses have been made to advance its clinical programs by Zacks
- ADXS: Pivotal Phase III planned, Balance sheet boosted; on track to advance its pipeline --Outperform by Zacks
- ADXS: Positive data presented at AACR, balance sheet strong ---Outperform by Zacks
- ADXS: clinical development plan outlined at analyst & investor day, balance sheet strong; - --Outperform by Zacks
- ADXS: Balance sheet boosted dramatically by new financing, on track to advance its pipeline with focus on ADXS-HPV cervical cancer, -- Outperform by Zacks
- AEMD: 5 Objectives Hit, New ADAPT Program To Broaden Applications by Zacks
- AEMD: Awarded DARPA Year 5 Contract by Zacks
- AEMD: CTE Study Published in Journal of Alzheimer s Disease by Zacks
- AEMD: Feasibility Study Nearing Completion, Pivotal U.S. Study Could Be Next by Zacks
- AEMD: Initiating With Neutral Rating by Zacks
- INUV: Zacks Company Report Initiating Coverage Turnaround Completed, Digital Ads Growth Follows by Zacks
- TEUM: Vodafone Now Marketing Pareteum’s MVNO Platform Worldwide by Zacks
- ABDC: Restructures Portfolio Away From Equities by Zacks
- ETAK: New Management Seeks Complete Overhaul to Right Size the Business by Zacks
- 1Q:16 Earnings Review and Financing Update by Zacks
- 2Q:16 Results. Waiting for Clarity on Resubmission Timeline. by Zacks
- ABDC: Discount to NAV Plus Healthy Dividend Yield; Initiating Coverage by Zacks
- ADMA: FDA Accepts BLA for RI-002 & Approves Second Plasma Collection Center… by Zacks
- ADMA: Initiating Coverage of ADMA Biologics, Inc. RI-002 on Track for 2016 FDA Approval by Zacks
- ADMA: The Year in Review & The Year Ahead by Zacks
- FDA s CRL Delays Approval of RI-002. No Issues with Clinical Safety or Efficacy Data. by Zacks
- 2012 Revenue Guidance In-Line With Our Model by Zacks
- ADXS: Balance sheet cleaned up and boosted
by new financial commitment, current pipeline
focus is ADXS-HPV cervical cancer---
Outperform by Zacks
- ADXS: Combination study further expands pipeline and could lead to license deals; Pivotal Phase III planned, Balance sheet strong; on track to advance its pipeline -- Outperform by Zacks
- ADXS: Multiple collaborations may lead to license deals; Pivotal Phase III planned, Balance sheet boosted; on track to advance its pipeline --Outperform by Zacks
- ADXS: Phase III of ADXS-HPV for cervical cancer will be initiated in mid-2016---Buy by Zacks
- ADXS: Positive data announced for anal caner, clinical development plan outlined, balance sheet strong; ---Outperform by Zacks
- ADXS: Phase III of ADXS-HPV for cervical cancer will be initiated in mid-2016 by Zacks
- ADXS: Great achievements made for ADXSHPV with two deals in two months. Balance sheet boosted dramatically by new financing, on track to advance its pipeline with focus on ADXS-HPV cervical cancer, --Outperform by Zacks
- AEMD: 5 Objectives Hit, New ADAPT Program To Broaden Applications by Zacks
- AEMD: $6M Raise. Reasonable Terms, Pipeline Development by Zacks
- AEMD: Balance Sheet Further De-Risked by Zacks
- AEMD: Cancer Gaining More Traction As Target for Hemopurifier by Zacks
- AEMD: Heading Into FY2016 With Accelerating Momentum by Zacks
- AEMD: More Shots On Goal For Hemopurifier, ESI CTE Diagnostic by Zacks